1
|
Owen DL, Morley JS, Ensor DM, Miles JB. The C-terminal tetrapeptide of beta-endorphin (MPF) enhances lymphocyte proliferative responses. Neuropeptides 1998; 32:131-9. [PMID: 9639251 DOI: 10.1016/s0143-4179(98)90028-2] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Human MPF (Lys-Lys-Gly-Glu) stimulates the proliferative response of human lymphocytes to the T-cell mitogen concanavalin A by 121-751% in the concentration range 10(-11)-10(-4) M; the peak effect is at 10(-8) M, lower or higher concentrations eliciting reduced responses, i.e. the dose-response curve is bell-shaped. Species specificity is high. Human MPF similarly stimulates rat lymphocytes, but the peak effect is seen at a 100-fold higher dose (10(-6) M). Rat MPF (Lys-Lys-Gly-Gln) has a peak effect at 10(-6) M with human lymphocytes, but the peak effect with rat lymphocytes is at a 1000-fold lower dose (10(-9) M). Truncated forms of the MPFs (Gly-Glu, Gly-Gln, Gly, Glu, Gln) and opioid peptides (beta-endorphin, [Leu] and [Met]enkephalin) show insignificant or only weak stimulatory or inhibitory effects. These results suggest that MPF acts via specific non-opioid receptors located on lymphocytes and that endogenously released MPF may have an important role in the functioning of the immune system.
Collapse
Affiliation(s)
- D L Owen
- Department of Evolutionary and Environmental Biology, University of Liverpool, UK
| | | | | | | |
Collapse
|
2
|
Woods JA, Shahabi NA, Sharp BM. Characterization of a naloxone-insensitive beta-endorphin receptor on murine peritoneal macrophages. Life Sci 1997; 60:573-86. [PMID: 9048961 DOI: 10.1016/s0024-3205(96)00640-6] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Previous studies from our laboratory have characterized a naloxone-insensitive beta-endorphin (beta-End) receptor on the human pro-monocytic cell line U937. Since monocytes are macrophage precursors, we sought to identify and characterize this site on fully differentiated effector macrophages. Mice (ICR females, 6-8 wk old) were injected (i.p.) with 1 mL of thioglycollate to induce an inflammatory response. Elicited cells were harvested 3 d later by lavage. Macrophages were enriched by adherence and analyzed via radioreceptor assay (with [125I] beta-End, 2,000 Ci mmol-1) as either intact cells or membrane preparations. Scatchard analysis revealed a single saturable binding site for beta-End (Kd = 9.75 +/- 2.6 x 10(-9) M; 8218 +/- 2360 sites/cell). Competition studies showed that other opiate receptor ligands including naloxone, DAMGO, U69593, or 2,5 DPDP-enkephalin were ineffective at displacing [125I] beta-End when compared to unlabeled beta-End. Analysis of competition studies utilizing fragments and analogs of beta-End revealed that beta-End (6-31) and beta-End (1-5, 16-31) were equipotent, and N-acetylated beta-End was less potent, than beta-end (1-31) in displacing [125I] beta-End binding. In contrast, beta-End (1-27) and beta-End (28-31) were ineffective. In summary, we have identified a naloxone-resistant beta-End binding site on murine peritoneal macrophages that is similar to one we have previously characterized on U937 cells and cultured murine splenocytes.
Collapse
Affiliation(s)
- J A Woods
- Endocrine-Neuroscience Research Laboratory, Minneapolis Medical Research Foundation, MN 55404, USA
| | | | | |
Collapse
|
3
|
Gelfand RA, Bobrow A, Pham L, Young C, Parker L. β-endorphin binding in cultured adrenal cortical cells. Endocrine 1995; 3:201-7. [PMID: 21153195 DOI: 10.1007/bf02994444] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/15/1994] [Accepted: 11/15/1994] [Indexed: 10/20/2022]
Abstract
The polypeptide β-endorphin binds to cultured bovine adrenal cortical cells in a naloxone insensitive manner, β-endorphin and N-Acetyl-β-endorphin are equipotent in inhibiting binding. The amino terminal 27 amino acid fragment referred to as β-endorphin[1-27] shows no ability to inhibit binding, whereas the carboxy-terminal tetrapeptide Lys-Lys-Gly-Glu partially inhibits binding. ACTH, angiotensin II and met-enkephalin show little or no ability to inhibit β-endorphin binding. Competition bin-ding reveals an apparently single affinity class with Kd of 33 nM. Molecular cross linking experiments reveal putative receptor subunits of 85 kD, 64 kD, 54 kD and 44 kD. The lower molecular weight bands are preferentially cross-linked by a hydrophobic cross linking reagent, in contrast to the two higher molecular weight bands, which are cross linked equally by hydrophobic and water soluble cross linking reagents. The β-endorphin binding characteristics of adrenal cortical cells revealed here are quite similar to those of a class of non-opioid β-endorphin receptors previously shown to exist in cells of the immune system.
Collapse
Affiliation(s)
- R A Gelfand
- Department of Veteran Affairs Medical Center, Endocrinology and Research Services, Long Beach, CA
| | | | | | | | | |
Collapse
|
4
|
Millington WR, Dybdal NO, Mueller GP, Chronwall BM. N-acetylation and C-terminal proteolysis of beta-endorphin in the anterior lobe of the horse pituitary. Gen Comp Endocrinol 1992; 85:297-307. [PMID: 1601261 DOI: 10.1016/0016-6480(92)90014-b] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
beta-Endorphin is post-translationally processed to both N-acetylated and C-terminally shortened derivatives in the anterior lobe of the horse pituitary, a processing pattern qualitatively different from that of the rat and virtually every other mammalian species. Thus, separation of the molecular forms of beta-endorphin using gel filtration and ion exchange chromatography showed that the horse anterior lobe primarily contains beta-endorphin-1-31 and N-acetyl-beta-endorphin-1-27 along with smaller amounts of beta-lipotropin, beta-endorphin-1-27, and N-acetyl-beta-endorphin-1-31 and -1-26, in contrast to the rat anterior lobe, which contains approximately equal amounts of beta-lipotropin and beta-endorphin-1-31. Immunohistochemical experiments using an antiserum which specifically recognizes N-acetylated beta-endorphin peptides confirmed that N-acetyl-beta-endorphin immunoreactivity is present in the anterior lobe of the horse, but not the rat. The intermediate lobe of both species primarily synthesizes N-acetylated, C-terminally shortened beta-endorphin peptides, and while distinct species differences do occur, they were relatively minor, consisting of quantitative differences in the relative proportion of each peptide. These results are consistent with earlier reports that beta-endorphin processing in the rat pituitary is tissue specific; the anterior and intermediate lobes produce entirely different sets of beta-endorphin peptides. In the equine pituitary, however, both pituitary lobes produce the same multiple beta-endorphin forms, possessing both opioid and nonopioid properties, although their relative amounts differ.
Collapse
Affiliation(s)
- W R Millington
- School of Basic Life Sciences, University of Missouri, Kansas City 64108
| | | | | | | |
Collapse
|
5
|
Abstract
beta-Endorphin is posttranslationally processed to six derivatives, which, although structurally similar, produce distinctly different biological effects. beta-Endorphin 1-31 is a potent opioid receptor agonist, but beta-endorphin 1-27 exhibits antagonist properties, and beta-endorphin 1-26 and the alpha-N-acetyl derivatives of all three peptides lack opioid receptor activity. In the present study, we identified the beta-endorphin peptides synthesized in human hypothalamus using cation exchange HPLC. First, we tested whether postmortem changes occur by storing rat hypothalami at 4 degrees C. This demonstrated that relative amounts of the six beta-endorphin forms did not change for up to 24 h, although total beta-endorphin immunoreactivity significantly declined after 6 h. HPLC analysis of human hypothalami revealed that beta-endorphin 1-31 was the principal form, constituting 58.4 +/- 5.4% of total immunoreactivity. Substantial amounts of beta-endorphin 1-27 (13.4 +/- 1.2%) and beta-endorphin 1-26 (13.1 +/- 1.6%) were also present, but alpha-N-acetylated forms were quantitatively minor, each comprising approximately 5% of total beta-endorphin. A similar processing pattern occurred in preoptic and suprachiasmatic areas of the hypothalamus. These results show that, despite differences in primary sequence, beta-endorphin is processed similarly in both rat and human hypothalamus. Opiate-active beta-endorphin 1-31 is the principal form in both species.
Collapse
Affiliation(s)
- W R Millington
- Division of Molecular Biology and Biochemistry, University of Missouri, Kansas City 64108-2792
| | | |
Collapse
|
6
|
Affiliation(s)
- W Gilmore
- Department of Neurology, University of Southern California School of Medicine, Los Angeles 90033
| | | | | |
Collapse
|
7
|
Hildebrand A, Preissner KT, Müller-Berghaus G, Teschemacher H. A novel β-endorphin binding protein. J Biol Chem 1989. [DOI: 10.1016/s0021-9258(19)84846-9] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
8
|
Hildebrand A. Identification of the beta-endorphin-binding subunit of the SC5b-9 complement complex: S protein exhibits specific beta-endorphin-binding sites upon complex formation with complement proteins. Biochem Biophys Res Commun 1989; 159:799-806. [PMID: 2467672 DOI: 10.1016/0006-291x(89)90065-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Beta-Endorphin has been reported to specifically interact with SC5b-9 complement complexes via non-opioid binding sites. Covalent cross-linking of [125I]beta H-endorphin to SC5b-9 and analysis of the cross-linking products by gel electrophoresis and subsequent autoradiography revealed a single specifically labelled species which was identical with the S protein subunit of the complement complex. In contrast to SC5b-9, no cross-linking of labelled beta-endorphin to subunits of C5b-9(m) could be observed, indicating that beta-endorphin binding to SC5b-9 was mediated exclusively via S protein. Beta-Endorphin binding to SC5b-9 was compared with binding to purified S protein. Whereas beta-endorphin binding to purified S protein was only modest, complex formation of S protein with complement proteins led to a strong increase in beta-endorphin-binding site concentration, compatible with the exposure of primarily cryptic beta-endorphin-binding sites on S protein.
Collapse
Affiliation(s)
- A Hildebrand
- Institut für Medizinische Mikrobiologie, Justus-Liebig-Universität, Giessen, F.R.G
| |
Collapse
|
9
|
Gilmore W, Weiner LP. The opioid specificity of beta-endorphin enhancement of murine lymphocyte proliferation. IMMUNOPHARMACOLOGY 1989; 17:19-30. [PMID: 2540118 DOI: 10.1016/0162-3109(89)90004-0] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Beta-endorphin (beta-end) is a potent analgesic peptide which exhibits a variety of pharmacological activities in the central nervous system (CNS) following binding of its N-terminus to specific opioid receptors. Although C-terminal binding sites for this 31-amino-acid peptide have been characterized in CNS tissue, identification of their possible function has been facilitated by studies of beta-end effects on lymphocyte activities. In this communication, we report a detailed analysis of the opioid specificity of the ability of beta-end to enhance T cell mitogen-induced proliferation in unfractionated murine splenocytes. Intact 31-amino-acid beta-end peptides from several species, including human, camel and rat, enhanced concanavalin A-stimulated [3H]thymidine uptake 50-640% in a dose-dependent, naloxone-irreversible fashion. The presence of the C-terminal amino acids was required for the enhancement activity, since met-enkephalin, alpha- and gamma-endorphin, and human beta-end 1-27 were ineffective. Accordingly, the truncated peptides, human beta-end 6-31 and 18-31, were also able to enhance the Con A response. However, human beta-end 18-31 was consistently not as effective as beta-end 6-31 or the intact 31-residue peptide. These data suggest that although the C-terminus contains the primary active sequence, the N-terminus contributes to the overall potency of the effect. In support of this assertion, N-acetylation, which abolishes opioid binding activity, resulted in a reduced magnitude of enhancement. The data suggest that beta-end interacts with a non-opioid receptor which has specificity characteristics strikingly similar to non-opioid receptors characterized in CNS tissue.
Collapse
Affiliation(s)
- W Gilmore
- Department of Neurology and Microbiology, USC School of Medicine, Los Angeles 90033
| | | |
Collapse
|
10
|
Srisuchart B, Fuchs BA, Sikorski EE, Munson AE, Loveless SE. Antitumor activity of enkephalin analogues in inhibiting PYB6 tumor growth in mice and immunological effects of methionine enkephalinamide. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY 1989; 11:487-500. [PMID: 2553621 DOI: 10.1016/0192-0561(89)90178-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Recent evidence has implicated enkephalins as immunomodulators. Several studies have reported the regulation of tumor growth by methionine enkephalin (ME). However, there has been little effort to relate the immunological significance of enkephalins to the development of anticancer drugs. The present study had three aims: first, to compare the antitumor activity of the synthetic peptide, D-[Ala2]methionine enkephalinamide (MEA), with endogenous enkephalins on PYB6 fibrosarcoma tumor growth; second, to determine whether tumor growth inhibition was mediated by an opiate receptor; and third, to investigate the effects of MEA on selected immune responses. Female B6C3F1 mice were injected i.p. daily for 7 days with 50-4000 micrograms/kg of ME, MEA, leucine enkephalin (LE) or D-[Ala2]leucine enkephalinamide (LEA), beginning 1 day after PYB6 inoculation. ME and MEA, but not LE or LEA, decreased the PYB6 growth rate. The dose of 50 micrograms/kg MEA exerted the maximum inhibition of tumor growth (nearly 72% on day 15 post tumor transplantation). MEA was not directly toxic to PYB6 tumor cells, as evaluated by the measurement of DNA synthesis and cellular ATP levels of PYB6 cells exposed to MEA in vitro. No [3H]-etorphine specific bindings were detected on the cell membrane or sonicates of splenic lymphocytes or PYB6 cells. Therefore, the antitumor activity by MEA is likely mediated by an indirect mechanism. Immunological studies indicated that MEA selectively enhanced the lymphoproliferative response to the T-cell mitogen, concanavalin A, but not to the B-cell mitogen, lipopolysaccharide.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- B Srisuchart
- Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298-0613
| | | | | | | | | |
Collapse
|
11
|
Hildebrand A, Schweigerer L, Teschemacher H. Characterization and identification of heparin-induced nonopioid-binding sites for beta-endorphin in human plasma. J Biol Chem 1988. [DOI: 10.1016/s0021-9258(18)69225-7] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
12
|
Lovegren ES, Ling N, Puett D. Interaction of alpha-N-Acetyl-beta-endorphin and calmodulin. JOURNAL OF PROTEIN CHEMISTRY 1988; 7:35-47. [PMID: 2855597 DOI: 10.1007/bf01025412] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Acetylation at the alpha-amino terminal is a common post-translational modification of many peptides and proteins. In the case of the potent opiate peptide beta-endorphin, alpha-N-acetylation is a known physiological modification that abolishes opiate activity. Since there are no known receptors for alpha-N-acetyl-beta-endorphin, we have studied the association of this peptide with calmodulin, a calcium-dependent protein that binds a variety of peptides, phenothiazines, and enzymes, as a model system for studying acetylated endorphin-protein interactions. Association of the acetylated peptide with calmodulin was demonstrated by cross-linking with bis(sulfosuccinimidyl)suberate; like beta-endorphin, adducts containing 1 mol and 2 mol of acetylated peptide per mole calmodulin were formed. Some of the bound peptides are evidently in relatively close proximity to each other since, in the presence of amidated (i.e., lysine-blocked) calmodulin, cross-linking yielded peptide dimers. The acetylated peptide exhibited no appreciable helicity in aqueous solution, but in trifluoroethanol (TFE) considerable helicity was formed. Also, a mixture of acetylated peptide and calmodulin was characterized by a circular dichroic spectrum indicative of induced helicity. Empirical prediction rules, applied earlier to beta-endorphin, suggest that residues 14-24 exhibit alpha-helix potential. This segment has the potential of forming an amphipathic helix; this structural unit is believed to be important in calmodulin binding. The acetylated peptide was capable of inhibiting the calmodulin-mediated stimulation of cyclic nucleotide phosphodiesterase (EC 3.1.4.17) activity with an effective dose for 50% inhibition of about 3 microM; this inhibitory effect was demonstrated using both an enzyme-enriched preparation as well as highly purified enzyme. Thus, acetylation at the alpha-amino terminal of beta-endorphin, although abolishing opiate activity, does not interfere with the binding to calmodulin. Indeed, beta-endorphin and the alpha-N-acetylated peptide behave very similarly with respect to calmodulin association.
Collapse
Affiliation(s)
- E S Lovegren
- Reproductive Sciences Laboratory, University of Miami School of Medicine, Florida 33101
| | | | | |
Collapse
|
13
|
Abstract
In the past few years it has become evident that neuropeptides may be direct mediators in the modulation of the immune response and the unspecific defense by the brain. Lymphocytes have been thought to have opioid receptors and to respond to opioids with an increase in blastogenesis, cytotoxicity and factor release. Lymphocytes are said to release various neuropeptides. Furthermore, there are some unexplained effects of morphine on the immune system and of the immune system on morphine withdrawal. The purpose of this paper is to review what has been previously published in this field. The well established modulation of phagocyte functions by opioids will only be scanned.
Collapse
Affiliation(s)
- E G Fischer
- Dept. of Pathology, RWTH-Klinkum, Aachen, Fed. Rep. Germany
| |
Collapse
|
14
|
Larsson LI. Regulatory peptides and amines during ontogeny and in non-endocrine cancers: occurrence and possible functional significance. PROGRESS IN HISTOCHEMISTRY AND CYTOCHEMISTRY 1988; 17:1-222. [PMID: 3062670 DOI: 10.1016/s0079-6336(88)80008-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- L I Larsson
- Department of Molecular Cell Biology, State Serum Institute, Copenhagen S/Denmark
| |
Collapse
|
15
|
Abstract
We looked for opioid peptides and their precursors in 108 tumors of both neuroendocrine and nonneuroendocrine origin, using a monoclonal "pan-opioid" antibody, 3-E7, which recognizes the tetrapeptide Tyr-Gly-Gly-Phe (the sequence responsible for pharmacologic activity in all known opioid peptides), in conjunction with polyclonal antibodies directed against representative peptides of each of the three precursors (alpha-endorphin, [met]enkephalin-Arg-Gly-Leu, and dynorphin B). Using the avidin-biotin immunoperoxidase technique, we observed consistent cytoplasmic immunoreactivity (at least focally) in all of 15 adrenal pheochromocytomas, all of 6 thyroid medullary carcinomas, and all of 5 pituitary adenomas. Opioid staining was also observed in parathyroid adenomas (8 of 9), pancreatic islet-cell tumors (7 of 10), carcinoid tumors from various sites (18 of 26), and paragangliomas (1 of 2). There was no immunoreactivity in pulmonary small-cell carcinomas, Merkel-cell tumors of skin, neuroblastomas, or any of the non-neuroendocrine tumors examined. The expression of alpha-endorphin, [met]enkephalin-Arg-Gly-Leu, and dynorphin B varied from tumor to tumor; however, positive staining with the "pan-opioid" antibody was found in each tumor containing at least one of the three precursors. Opioid peptide immunoreactivity was also detected in non-neoplastic cells of the adrenal medulla, pancreatic islets, pituitary, intestinal and bronchial mucosa, and intestinal myenteric plexuses. We conclude that opioid expression within tumors is most likely due to enhanced expression of a normal cell product and that opioid peptides are useful markers of neuroendocrine differentiation in many tumors.
Collapse
Affiliation(s)
- D G Bostwick
- Department of Pathology, University of Chicago Medical Center
| | | | | | | | | | | |
Collapse
|
16
|
Richter WO, Schwandt P. Melanotropin potentiating factor inhibits lipolytic activity of beta-lipotropin but not of melanocyte stimulating hormones. Neuropeptides 1986; 7:73-7. [PMID: 3951681 DOI: 10.1016/0143-4179(86)90081-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Melanotropin potentiating factor (MPF) potentiates the melanotropic activity of melanocyte stimulating hormones. Although the message sequence for the melanotropic and lipolytic activity are identical for beta-lipotropin, alpha- and beta-MSH, MPF was not able to affect the lipolytic response to alpha- and beta-MSH in rabbit adipocytes. However, MPF at concentrations of 10-5 and 10-6 mol/l inhibited the lipolytic activity of beta-lipotropin. This suggests that the inhibition of the lipolytic response to beta-lipotropin is not connected with the common lipolytic message sequence (beta-LPH 47-53). Since beta-lipotropin has a second lipolytic sequence in its C-terminal part this second lipolytic core of beta-lipotropin might interact with MPF which has no intrinsic lipolytic activity.
Collapse
|
17
|
Westphal M, Li CH. Human retinoblastomas have binding sites for the COOH-terminal segment of human beta-endorphin. INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH 1985; 26:557-9. [PMID: 3002997 DOI: 10.1111/j.1399-3011.1985.tb01023.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Two human retinoblastoma cell lines (Y79 and McA) were evaluated for the presence of binding sites for human beta-endorphin (beta h-EP). Using tritiated beta h-EP (3H-beta h-EP) and synthetic beta-EP analogues, it was possible to demonstrate binding sites for 3H-beta h-EP with an ED50 of 3.5 nM in Y79 cells and 8 nM in McA cells respectively. The non-opioid segment [beta h-EP-(6-31)] retained about 20% relative potency in Y79 and 40% in McA in displacing the tritiated hormone when compared with beta h-EP. Camel beta-EP had a relative potency of less than 1% and beta h-EP-(1-27) was inactive in both cells in doses as high as 4 microM. Taken together with previous reports on similar binding sites in human neuroblastoma and glioblastoma cell lines, it appears that cell lines of neural origin have binding sites for the COOH-terminal of human beta-EP.
Collapse
|
18
|
Schweigerer L, Schmidt W, Teschemacher H, Wilhelm S. Beta-endorphin: interaction with specific nonopioid binding sites on EL4 thymoma cells. Neuropeptides 1985; 6:445-52. [PMID: 2997656 DOI: 10.1016/0143-4179(85)90143-x] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Binding of 125I-labeled camel beta-endorphin (125I-beta C-endorphin) to cells of several mouse thymoma cell lines was examined and was highest to EL4 cells. 125I-beta C-endorphin binding to EL4 cells was temperature-dependent; it was further characterized at 4 degrees C and exhibited saturability, complete reversibility, structural specificity and pH-dependence. 125I-beta C-endorphin binding was not inhibited by the opioid pentapeptides [Leu] enkephalin or [Met] enkephalin (which share common sequences with the N-terminus of beta C-endorphin) or by the N-terminal beta C-endorphin fragments beta C-endorphin (1-16) or beta C-endorphin (1-27). In contrast, binding was inhibited by beta C-endorphin (1-31), indicating that beta C-endorphin binding to EL4 cells was with a C-terminal beta C-endorphin segment. We suggest that binding of beta-endorphin to such nonopioid binding sites may precede its apparent effects on the proliferation of T-lymphocytes (5,6).
Collapse
|
19
|
Moises HC, Walker JM. Electrophysiological effects of dynorphin peptides on hippocampal pyramidal cells in rat. Eur J Pharmacol 1985; 108:85-98. [PMID: 2858395 DOI: 10.1016/0014-2999(85)90286-9] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Single-unit extracellular recording was carried out in rats to characterize the effects of dynorphin and several structurally related peptides on hippocampal pyramidal cell activity. Dynorphin, applied electrophoretically or by pneumatic pressure, produced a dose-dependent depression of both spontaneous and glutamate-evoked discharge in a majority (63%) of CA1 and CA3 cells tested. In addition, a small number of cells in both cellular fields responded to the peptide with a prolonged elevation in firing. The inhibitory effects of dynorphin were not blocked by naloxone. Moreover, administration of des-tyrosine-dynorphin depressed the firing of pyramidal cells in a manner similar to that of the parent compound. Ethylketocyclazocine produced a mixed pattern of excitatory and inhibitory effects, whereas naloxone-sensitive elevations in firing were most often observed with the application of dynorphin-(1-8). Application of [Leu5]enkephalin produced only facilitations in pyramidal cell firing. The possibility is raised that biologically significant non-opiate actions, in addition to potent opiate-mediated effects, may occur upon release of pro-dynorphin peptides in the hippocampus.
Collapse
|
20
|
|
21
|
Westphal M, Li CH. beta-Endorphin: evidence for the existence of opioid and non-opioid binding components for the tritiated human hormone in NG108-15 cells. Biochem Biophys Res Commun 1984; 122:428-33. [PMID: 6331452 DOI: 10.1016/0006-291x(84)90493-5] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Human beta-endorphin (beta h-EP) binding on neuroblastoma X glioma hybrid NG108-15 cells using tritiated human beta endorphin (3H-beta h-EP) as a primary ligand was found to have a component which was not displacable with [D-Ser2 )-Leu-enkephalin-Thr6 (DSLET). The beta h-EP binding on these cells after saturation of the delta opiate sites with 200 nM DSLET was further characterized with synthetic beta h-EP analogs. The nonopioid binding site appears to recognize beta h-EP-(6-31), beta h-EP-(21-31) and beta h-EP-(28-31). Under these conditions, these COOH-terminal segments fully displace the tritiated beta h-EP. However, beta h-EP-(1-27) does not further displace 3H-beta h-EP in the presence of DSLET. The fact that a combination of DSLET and beta h-EP-(6-31) results in a full displacement of 3H-beta h-EP provides direct evidence for the existence of two binding sites for beta h-EP in NG108-15 cells, one recognizing the NH2-terminal enkephalin sequence and the other the non-opioid COOH-terminal segment.
Collapse
|
22
|
|
23
|
Westphal M, Li CH. Beta-endorphin: demonstration of binding sites in three human neuroblastoma cell lines specific for the COOH-terminal segment of the human hormone. Biochem Biophys Res Commun 1984; 120:873-8. [PMID: 6329187 DOI: 10.1016/s0006-291x(84)80188-6] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
This communication reports for the first time specific binding sites in human neuroblastoma cells for human beta-endorphin (beta h-EP). Three cell lines (IMR-32, NMB and Kelly) were investigated and found to bind tritiated beta h-EP with an apparent dissociation constant of 2.2-4.2 nM. Further characterization with camel beta-EP and synthetic analogs indicated that the binding is most likely mediated by the COOH-terminal segments. beta h-EP-(6-31) had significant potency (15-75%) and beta h-EP-(1-27) was without displacing activity. The camel beta-EP has below 1% of the human beta-EP activity.
Collapse
|